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Raising the level of HDL cholesterol has been proposed as a potential 
therapeutic strategy to reduce cardiovascular risk, largely based on the 
epidemiological studies showing that low HDL cholesterol levels are associated with 
an increased risk of coronary disease and cardiovascular events (1, 2) this has been 
supported by experimental as well as translational studies studies which has 
demonstrated anti-atherogenic properties of HDL (3). This led to the perception of 
HDL cholesterol as the “good cholesterol”. Notably, in the Treating to New Targets 
(TNT) study, low HDL cholesterol levels remained a marker of increased 
cardiovascular risk even in coronary patients with low LDL cholesterol levels (< 70 
mg per deciliter) on statin therapy (2). 
   While initial studies proposed reverse macrophage cholesterol transport by 
HDL as the main anti-atherogenic mechanism (4), more recent studies highlighted 
endothelial-protective properties of HDL, including stimulation of endothelial nitric 
oxide (NO) production, as well as anti-inflammatory, anti-apoptotic and anti-
thrombotic effects (5, 6).  Importantly, however, these studies have used HDL 
isolated from healthy subjects or reconstituted HDL  which differ in several ways 
from HDL obtained from patients with coronary disease, as discussed below.  
 Inhibition of cholesteryl ester transfer protein (CETP) offers an unprecedented 
opportunity to increase profoundly HDL cholesterol plasma levels (7). This has 
resulted in several large scale programs to explore the potential of CETP as a novel 
therapeutic target for cardiovascular prevention. The large randomized ILLUMINATE 
trial examined the effects of the CETP inhibitor torcetrapib on clinical outcomes in 
15,067 patients at high cardiovascular risk. In spite of a marked increase in plasma 
HDL cholesterol levels of 72.1 %, the trial had to be stopped due to increased 
mortality and morbidity in the treatment group (8). In subsequent mechanistic 
studies, the adverse effects of torcetrapib were attributed to off-target toxicity, in 
particular increased production of aldosterone as well as an increased production of 
endothelin and reduced expression of endothelial nitric oxide synthase in the vessel 
wall (9). These off-target effects of torcetrapib were held responsible for the 
observed increase in arterial blood pressure with this agent (8).  Two posthoc 
analyses, the first in ILLUMINATE and the second in ILLUSTRATE, the coronary 
IVUS study with torcetrapib, indicated that those participants with the highest 
increase of HDL cholesterol or achieved on-treatment HDL cholesterol levels did 
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show cardiovascular benefit. This raised hopes that other CETP inhibitors without 
the off-target toxicity of torcetrapib would lead to prevention of recrurrent events (8, 
10, 11).  
 
The dal-HEART program  was a carefully designed clinical development 
program of another CETP inhibitor, dalcetrapib, that to the surprise of many was 
stopped on Saturday, 5th May 2012.  The interim analysis of the large phase-3 dal-
OUTCOMES trial, involving more than 15’600 patients with recent acute coronary 
syndrome, had revealed lack of efficacy in reducing cardiovascular events (12). This 
clinical trial program was the first development program of a CETP inhibitor after the 
torcetrapib failure. With this experience in mind, two safety studies, the dal-VESSEL 
and the dal-PLAQUE studies, designed to exclude adverse vascular effects of the 
compound, were part of the early development programme (13, 14).  Whereas both 
studies did not reveal adverse vascular effects of dalcetrapib therapy neither on 
endothelial function as assessed by flow-mediated dilation nor on vascular structure 
as examined by carotid MRI, there was also not a convincing signal that the 
compound would exert protective effects on these parameters (13, 14).  
Indeed, inspite of a marked increase in HDL cholesterol plasma levels by 30% 
and a lack of effect on blood pressure, endothelial function was not improved (as had 
been the case with reconstituted HDL. (15)) Similarily, despite a suggestion of 
potential benefit  plaque size and inflammation (as assessed by positron emission 
tomography using fluoro-desoxyglucose as tracer) were largely affected by the drug. 
Unfortunately, these findings had received little attention, although they now appear 
in strong agreement with the neutral outcome of the phase-3 clinical trial.    
 Another more potent CETP inhibitor, anacetrapib, is currently developed by 
Merck and is being tested in a large phase 3 clinical program (see ClinicalTrials.gov 
Identifier: NCT01252953) after the long-term safety study DEFINE revealed 
encouraging results on blood pressure and lipids (16).  Furthermore, Eli Lilly’s 
evacetrapib has also entered a clinical trial program (17). While dalcetrapib only 
increased HDL cholesterol relatively modestly, both anacetrapib and evacetrapib 
also markedly lower LDL cholesterol, small dense LDL, lipoprotein (a), non-HDL 
cholesterol and apolipoproteinB, even on top of potent statin therapy (Table).  
Moreover, a very recent and large Mendelian randomization study has confirmed 
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that lower CETP activity, when associated with both lower LDL and higher HDL, is 
associated with cardiovascular benefit (18).  
Interpretation and prediction of the impact of CETP-inhibitons is complicated by 
the growing awareness that the effects of HDL cholesterol may vary in different 
clinical settings. For example the effects of HDL cholesterol on macrophage 
cholesterol efflux and in particular the endothelial effects of HDL cholesterol are 
altered in patients with coronary disease or diabetes as well other inflammatory 
conditions, a phenomenon referred to as “HDL dysfunction” (3). Indeed, Khera et al. 
found that the cholesterol efflux capacity of apoB-depleted serum (as a measure of 
the capacity of HDL to accept cholesterol from macrophages) was inversely related 
to carotid intima-media thickness and the likelihood of angiographic coronary artery 
disease independent of the HDL cholesterol plasma levels (19).  We have observed 
that that the capacity of HDL to stimulate endothelial NO production and endothelial 
repair is substantially reduced in patients with coronary artery disease or diabetes 
mellitus (20, 21). Of note, HDL, isolated from healthy subjects, substantially 
stimulated endothelial cell NO production and accelerated endothelial repair in vivo, 
whereas no such or even opposite effects were observed when HDL was isolated 
from patients with coronary disease or diabetes (20, 21). The underlying 
mechanisms need to be further defined, but likely include increased lipid oxidation of 
HDL due to a reduced HDL-associated paraoxonase-1 activity, an enzyme that 
protects HDL from lipid oxidation, as well as modifications of the protein moiety. HDL 
is a highly complex lipoprotein that can scavenge more than 70 proteins, as 
identified by proteomics analysis (22), and may contain more than 1000 different lipid 
species with each of them being modifiable. The vascular effects of HDL are not 
necessarily predictable by simply measuring its cholesterol concentration, since 
cholesterol is only a non-functional cargo of this lipoprotein and hence a surrogate 
marker reflecting the size and number of HDL particles. These observations raise the 
possibility that the vascular effects of on-treatment HDL may be an important 
determinant of the overall cardiovascular benefits of an HDL-raising intervention. 
Indeed, an increase in the plasma levels of dysfunctional HDL particles by interfering 
with their catabolism through CETP inhibition may in fact be detrimental. Hence, both 
the on-treatment vascular effects of HDL as well as the underlying molecular 
mechanism leading to increased HDL cholesterol levels are likely important 
determinants of the overall vascular effects of an HDL-cholesterol raising therapeutic 
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intervention.  Thus, targeting HDL cholesterol by CETP inhibition remains a “rocky 
road”. It appears that we need to learn more about the biology of HDL and its relation 
to atherosclerotic vascular disease. Notably easy-to-measure biomarkers reflecting 
HDL functionality better than HDL cholesterol or apoA-I levels are urgently needed. 
In this regard, post hoc analyses of Dal-OUTCOME and its biobank may turn out as 
a highly valuable resource towards better understanding of the dalcetrapib failure.  
The extensive dal-HEART program included early safety studies with surrogate 
measures as an endpoint to detect potential adverse effects of dalcetrapib early on. 
It is noteworthy that the dal-VESSEL study showed no evidence of adverse vascular 
effects (similar to those with torcetrapib) but also no evidence of benefit on vascular 
function. The dal-PALQUE study showed some weak effects on the carotid wall. 
Atherosclerosis progress for many years before clinical events and involves 
dysfunctional vascular biology characterised by inflammation and endothelial 
dysfunction. In hindsight, the lack of a convincing positive signals from the two 
studies of function and structure should have been given more weight.  
Such studies in the future should perhaps be included in development programs for 
drugs which target novel mechanisms for atherosclerosis modification and 
cardiovascular risk reduction. 
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